Colorado's Drug Price Cap Under Fire

Colorado’s bold move to cap prescription drug prices is under legal fire, with Amgen suing over its cap on Enbrel—a drug that brought in over $2 billion. A federal judge now weighs whether the state’s Prescription Drug Affordability Board violates federal patent law, amid confusion over how drug pricing really works and whether price caps truly hurt innovation or just shift costs around. The ruling could set a national precedent for how states tackle skyrocketing drug costs. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c66f412ce3c22e35